Renalogic provides chronic kidney disease management and dialysis cost containment services to self-funded health plans across the United States. Founded in 2002, the company has spent over two decades developing Population Health Management programmes that combine clinical services with cost-control strategies. Its NCQA-accredited clinical services are designed to identify undiagnosed CKD early and prevent progression to end-stage renal disease requiring dialysis.
The company's flagship offering, ImpactCare, takes a preventive approach to CKD management through early detection, clinical support, and administrative guidance. According to the company, ImpactCare identifies undiagnosed chronic kidney disease 230% more effectively than standard approaches and reduces emergent dialysis starts by 30% - a material outcome given that dialysis costs often exceed $100,000 per patient annually. The programme combines data-driven analytics with case management support tailored to self-funded plan sponsors.
Renalogic's team spans clinical experts in renal disease, healthcare administrators, case managers, and legal specialists in ERISA and healthcare law. The company positions itself as a partner to health plans seeking to manage the clinical and financial burden of chronic kidney disease, which affects millions of Americans.
